IMRX vs. GOSS

Last updated Apr 1, 2026

Compare and contrast key facts about Immuneering Corporation (IMRX) and Gossamer Bio, Inc. (GOSS).

Performance

IMRX vs. GOSS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immuneering Corporation (IMRX) and Gossamer Bio, Inc. (GOSS). The values are adjusted to include any dividend payments, if applicable.

IMRX vs. GOSS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
IMRX Immuneering Corporation	-19.91%	199.09%	-70.07%	51.55%	-70.01%	-8.07%
GOSS Gossamer Bio, Inc.	-89.40%	242.69%	-0.87%	-57.95%	-80.81%	43.89%

Fundamentals

EPS IMRX : -$1.20 GOSS : -$0.69
Total Revenue (TTM) IMRX : $0.00 GOSS : $44.05M
Gross Profit (TTM) IMRX : -$86.16K GOSS : $44.05M
EBITDA (TTM) IMRX : -$58.69M GOSS : -$145.96M

Returns By Period

In the year-to-date period, IMRX achieves a -19.91% return, which is significantly higher than GOSS's -89.40% return.

IMRX

• 1D: 7.99%
• 1M: 5.61%
• YTD: -19.91%
• 6M: -24.71%
• 1Y: 246.71%
• 3Y*: -18.43%
• 5Y*: —
• 10Y*: —

GOSS

• 1D: 2.66%
• 1M: -22.69%
• YTD: -89.40%
• 6M: -87.51%
• 1Y: -70.14%
• 3Y*: -36.12%
• 5Y*: -48.81%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

IMRX vs. GOSS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMRX

IMRX Risk / Return Rank: 89
IMRX Sharpe Ratio Rank: 91
IMRX Sortino Ratio Rank: 89
IMRX Omega Ratio Rank: 89
IMRX Calmar Ratio Rank: 90
IMRX Martin Ratio Rank: 84

GOSS

GOSS Risk / Return Rank: 19
GOSS Sharpe Ratio Rank: 17
GOSS Sortino Ratio Rank: 31
GOSS Omega Ratio Rank: 31
GOSS Calmar Ratio Rank: 13
GOSS Martin Ratio Rank: 1

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMRX vs. GOSS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immuneering Corporation (IMRX) and Gossamer Bio, Inc. (GOSS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IMRX	GOSS	Difference
Sharpe ratio Return per unit of total volatility	1.99	-0.57	+2.56
Sortino ratio Return per unit of downside risk	2.74	0.04	+2.70
Omega ratio Gain probability vs. loss probability	1.39	1.01	+0.38
Calmar ratio Return relative to maximum drawdown	4.00	-0.79	+4.78
Martin ratio Return relative to average drawdown	7.67	-2.06	+9.73
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IMRX vs. GOSS - Sharpe Ratio Comparison

The current IMRX Sharpe Ratio is 1.99, which is higher than the GOSS Sharpe Ratio of -0.57. The chart below compares the historical Sharpe Ratios of IMRX and GOSS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	IMRX	GOSS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.99	-0.57	+2.56
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.49	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.20	-0.47	+0.27

Correlation

The correlation between IMRX and GOSS is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

IMRX vs. GOSS - Dividend Comparison

Neither IMRX nor GOSS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

IMRX vs. GOSS - Drawdown Comparison

The maximum IMRX drawdown since its inception was -96.86%, roughly equal to the maximum GOSS drawdown of -98.81%. Use the drawdown chart below to compare losses from any high point for IMRX and GOSS.

Drawdown Indicators

	IMRX	GOSS	Difference
Max Drawdown Largest peak-to-trough decline	-96.86%	-98.81%	+1.95%
Max Drawdown (1Y) Largest decline over 1 year	-55.35%	-91.56%	+36.21%
Max Drawdown (5Y) Largest decline over 5 years	—	-97.85%	—
Current Drawdown Current decline from peak	-83.95%	-98.77%	+14.82%
Average Drawdown Average peak-to-trough decline	-77.37%	-70.70%	-6.67%
Ulcer Index Depth and duration of drawdowns from previous peaks	28.85%	34.87%	-6.02%

Volatility

IMRX vs. GOSS - Volatility Comparison

The current volatility for Immuneering Corporation (IMRX) is 17.99%, while Gossamer Bio, Inc. (GOSS) has a volatility of 39.73%. This indicates that IMRX experiences smaller price fluctuations and is considered to be less risky than GOSS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IMRX	GOSS	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.99%	39.73%	-21.74%
Volatility (6M) Calculated over the trailing 6-month period	75.99%	173.90%	-97.91%
Volatility (1Y) Calculated over the trailing 1-year period	125.17%	124.02%	+1.15%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	115.64%	100.18%	+15.46%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	115.64%	92.33%	+23.31%

Financials